Recurrent seizure‐related GRIN1 variant: Molecular mechanism and targeted therapy
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objective: Genetic variants in the GRIN genes that encode N‐methyl‐D‐aspartate receptor (NMDAR) subunits have been identified in various neurodevelopmental disorders, including epilepsy. We identified a GRIN1 variant from an individual with early‐onset epileptic encephalopathy, evaluated functional changes to NMDAR properties caused by the variant, and screened FDA‐approved therapeutic compounds as potential treatments for the patient. Methods: Whole exome sequencing identified a missense variant in GRIN1. Electrophysiological recordings were made from Xenopus oocytes and transfected HEK cells to determine the NMDAR biophysical properties as well as the sensitivity to agonists and FDA‐approved drugs that inhibit NMDARs. A beta‐lactamase reporter assay in transfected HEK cells evaluated the effects of the variant on the NMDAR surface expression. Results: A recurrent de novo missense variant in GRIN1 (c.1923G>A, p.Met641Ile), which encodes the GluN1 subunit, was identified in a pediatric patient with drug‐resistant seizures and early‐onset epileptic encephalopathy. In vitro analysis indicates that GluN1‐M641I containing NMDARs showed enhanced agonist potency and reduced Mg 2+ block, which may be associated with the patient’s phenotype. Results from screening FDA‐approved drugs suggested that GluN1‐M641I containing NMDARs are more sensitive to the NMDAR channel blockers memantine, ketamine, and dextromethorphan compared to the wild‐type receptors. The addition of memantine to the seizure treatment regimen significantly reduced the patient’s seizure burden. Interpretation: Our finding contributes to the understanding of the phenotype–genotype correlations of patients with GRIN1 gene variants, provides a molecular mechanism underlying the actions of this variant, and explores therapeutic strategies for treating GRIN1‐related neurological conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · cited 4×
“1,2,4,7,8 ,9-16 The rapid technical advances in next-generation whole-exome sequencing have increased the number of diseased-related GRIN variants identified.”
BackgroundMethodInfluentialSelf-citationNMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
Paoletti, P., Bellone, C., & Zhou, Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3504 · Cited by 2,523 · cited 1×
“1,2,4,7,8 ,9-16 The rapid technical advances in next-generation whole-exome sequencing have increased the number of diseased-related GRIN variants identified.”
BackgroundNMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders
Lau, C. G., & Zukin, R. S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2153 · Cited by 1,159 · cited 1×
“The malfunction of NMDARs has been proposed to associate with a wide range of pathological conditions.(1,2,4,7,8) De novo GRIN1 variants have been identified in a set of neurological diseases, including developmental delay, intellectual disability, epilepsy, autism-spectrum disorders, hypotonia, and movement disorders.”
BackgroundStructure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Self-citationDelineating the GRIN1 phenotypic spectrum: A distinct genetic NMDA receptor encephalopathy
Lemke, J. R., Geider, K., Helbig, K. L., Heyne, H. O., Schütz, H., Hentschel, J., Courage, C., Depienne, C., Nava, C., Heron, D., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002740 · Cited by 200
Mullier, B., Wolff, C., Sands, Z. A., Ghisdal, P., Muglia, P., Kaminski, R. M., & André, V. M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.017 · Cited by 65
Cited by
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Self-citationDevelopmental and epileptic encephalopathies
Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 158
Spectrum of NMDA receptor variants in neurodevelopmental disorders and epilepsy
Gjerulfsen, C. E., Krey, I., Klöckner, C., Rubboli, G., Lemke, J. R., & Møller, R. S. (2024) · Methods in Molecular Biology · doi:10.1007/978-1-0716-3830-9_1 · Cited by 11
Metadata
- Authors
- Xu, Y., Song, R., Chen, W., Strong, K., Shrey, D., Gedela, S., Traynelis, S. F., Zhang, G., & Yuan, H.
- Venue
- Annals of Clinical and Translational Neurology
- Publisher
- Wiley
- Published
- 2021-07
- Volume
- 8
- Issue
- 7
- Pages
- 1480-1494
- ISSN
- 2328-9503 (ISSN-L)
- OpenAlex
- W3178843692
- Cited by
- 38
- References
- 7
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recurrent seizure‐related GRIN1 variant: Molecular mechanism and targeted therapy. https://app.cochat.ai/papers/10.1002/acn3.51406
- The paper
- Xu, Y., Song, R., Chen, W., Strong, K., Shrey, D., Gedela, S., Traynelis, S. F., Zhang, G., & Yuan, H. (2021). Recurrent seizure‐related GRIN1 variant: Molecular mechanism and targeted therapy. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.51406
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.